When I think about the work we do at Jazz Pharmaceuticals, I find myself reflecting on the patients and families navigating the daily realities of rare and severe, treatment-resistant epilepsies. Our work is guided by a simple conviction: every person living with a complex neurological condition, and those who care for them, deserve the opportunity to live their life as fully as possible. These stories inspire us to look beyond seizures to what else matters in their daily lives.
Historically, success in epilepsy care was measured through the singular lens of reducing the frequency of seizures. While decreasing seizures will always be important, true progress requires going further. The hallmark of developmental and epileptic encephalopathies, including Lennox-Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex, is how the conditions impact patients beyond seizure burden. These conditions affect cognition, communication, behavior and sleep, contributing to the overall complexity of disease management.1
Listening closely to patients, caregivers and clinicians has reinforced that treatments should address the broader impact of these conditions. This has taught us that a comprehensive assessment of treatment benefit should consider outcomes beyond seizure frequency.
In addition to addressing these life outcomes, to better serve the epilepsy community we must also acknowledge a critical and underrecognized challenge: the adult diagnostic gap. Although severe epilepsy syndromes are often viewed as pediatric conditions, they are lifelong.2 Many adults, particularly those in long-term care or transitioning from pediatric settings, lack a formal, syndrome-specific diagnosis decades after seizure onset. Without an accurate or updated diagnosis, this can limit opportunities for optimized management, research participation and access to clinical advances in genetically defined epilepsies that might offer syndrome-specific treatment approaches.
Empowering clinicians with the education and tools needed to identify these conditions across all age groups is essential to expanding care and closing this gap. Jazz’s award-winning See A Seizure campaign demonstrates how we are putting our community commitment into action. Through visual simulations of real-world seizure representations, the initiative helps identify subtle seizure activity that might otherwise be overlooked.
Meaningful progress requires us to continuously redefine what’s possible. By listening to patients, care teams and leading experts, we can better understand community needs and use what we learn to shape our research priorities.
Together these community insights guide our early-stage research, including better understanding the underlying biology for specific genetic and syndrome-specific diagnoses to develop precision therapies, while recognizing the need for treatment options which offer greater flexibility, administration options, and age-appropriate delivery throughout patients’ lives. With more specific diagnoses and treatment options, clinicians can tailor care and guide management to improve outcomes and address their patients holistically.
Every day, we stand alongside the epilepsy community. By uniting scientific rigor with empathy, we’ll continue to listen, innovate and advocate to elevate standards of care and redefine what is possible for people living with rare and severe epilepsies, across every stage of life.
الإبلاغ عن أثر جانبي
إذا كنت ترغب في الإبلاغ عن أثر جانبي مرتبط بالمنتجات الدوائية لشركة Jazz Pharmaceuticals، يُرجى إرسال بريد إلكتروني إلينا عبر الرابط التالي:
يُرجى تقديم أكبر قدر ممكن من المعلومات المتاحة.
تشمل المعلومات ذات الصلة ما يلي:
بتقديمك لتقريرك وتزويدنا ببيانات الاتصال الخاصة بك، فإنك تُقرّ وتوافق صراحةً على أنه يجوز لقسم السلامة الدوائية المحلي التواصل معك بغرض طلب معلومات إضافية أو توضيحات، إذا اعتُبر ذلك ضروريًا لتقييم التقرير ومتابعته.
يوضح إشعار الخصوصية الخاص بنا المتعلق باليقظة الدوائية والمعلومات الطبية وشكاوى المنتجات كيفية تعامل شركة Jazz Pharmaceuticals مع معالجة المعلومات الشخصية عند التعامل مع تقريرالأثر الجانبي الخاص بك، وهو متاح في مركز الخصوصية لدينا.
Report an Adverse Event
If you want to report a Adverse Event related to Jazz Pharmaceuticals medicinal products, then please send us an e-mail via this link:
Please provide as much available information as possible.
Relevant information includes:
By submitting your report and providing your contact details, you expressly acknowledge and agree that the local drug safety department may contact you for the purpose of requesting additional information or clarifications, should this be deemed necessary for the assessment and follow‑up of the report.
Our Privacy Notice for Pharmacovigilance, Medical Information and Product Complaints outlines how Jazz Pharmaceuticals handles the processing of personal information when dealing with your adverse event report and is available in our Privacy Center.